nitazoxanide has been researched along with Acute Relapsing Multiple Sclerosis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butler, E; Butzkueven, H; Buzzard, K; Eichau, S; Girard, M; Hodgkinson, S; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Monif, M; Oh, J; Prevost, J; Skibina, O; van der Walt, A; Van Pesch, V; Zhong, M | 1 |
| Anand, B; Annadure, RK; Arulselvan, V; Deepalam, S; Gupta, S; Ichaporia, N; Iyer, RB; John, SK; Kamath, V; Kumar, S; Mathew, T; Murgod, U; Nadig, R; Nair, SS; Neeharika, ML; Netravathi, M; Parry, G; Raghavendra, S; Reddy, YM; Renukaradhya, U; Rohatgi, A; Sarma, GRK; Satishchandra, P; Sharath Kumar, GG; Shivakumar, R; Singh, P; Singhal, BS; Surya, N; Yareeda, S | 1 |
| Auer, M; Bauer, A; Berek, K; Berger, T; Bsteh, G; Deisenhammer, F; Di Pauli, F; Hegen, H; Oftring, A; Reindl, M; Rudzki, D; Zinganell, A | 1 |
| Hemmer, B; Höfler, J; Hornuss, C; Liedert, B; Roth, K; Selmaj, K; Wessels, H; Wiendl, H | 1 |
| Arroyo-Pereiro, P; Bau, L; León, I; Martínez-Yélamos, A; Martínez-Yélamos, S; Matas, E; Muñoz-Vendrell, A; Romero-Pinel, L | 1 |
2 trial(s) available for nitazoxanide and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.
Topics: Adult; Biosimilar Pharmaceuticals; Female; Gadolinium; Humans; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neoplasm Recurrence, Local; Recurrence; Treatment Outcome | 2023 |
Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
Topics: Humans; Immunologic Factors; JC Virus; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Risk Assessment | 2023 |
3 other study(ies) available for nitazoxanide and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Topics: Chronic Disease; Cladribine; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2023 |
A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis.
Topics: Adolescent; Adult; Female; Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitro Compounds; Thiazoles | 2022 |
Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab.
Topics: Biomarkers; Humans; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitro Compounds; Retrospective Studies; Thiazoles; Vascular Cell Adhesion Molecule-1 | 2022 |